Alembic Pharma's Generic Methotrexate Injection Gets FDA Approval

USFDA Approval for Methotrexate Injection

The U.S. Food and Drug Administration has granted final approval to Alembic Pharmaceuticals for its generic version of methotrexate injection. This development strategically strengthens the company's presence in the significant oncology and autoimmune disease markets. The approved Abbreviated New Drug Application (ANDA) covers two critical dosage formats: 50 mg/2 ml multi-dose vials and 1g/40 ml single-dose vials. These generics are therapeutically equivalent to the reference listed drug originally marketed by Hospira, Inc. Methotrexate injection is used for various cancers, including acute lymphoblastic leukemia, meningeal leukemia, osteosarcoma, and breast cancer. Beyond oncology, it is also used to treat chronic inflammatory and autoimmune disorders such as rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and severe psoriasis.

Pipeline Expansion and Financial Snapshot

This USFDA approval adds another product to Alembic's U.S. generics pipeline, which now totals 235 ANDAs, with 217 receiving final approval. Historically, such regulatory clearances have typically led to modest stock price movements for Alembic, usually between 1-5%. The company's stock price was trading around ₹734.80 as of April 15, 2026, having recently risen 2.42% from its previous close. As of mid-April 2026, Alembic Pharmaceuticals had a market capitalization of approximately ₹14,232.9 crore and a Price-to-Earnings (P/E) ratio around 22.68.

Market Landscape and Competitive Pressures

Alembic is entering the established global methotrexate market, valued at an estimated USD 0.547 billion in 2026 and projected to reach USD 0.703 billion by 2035, growing at a compound annual growth rate (CAGR) of 2.8%. North America, particularly the U.S., accounts for a substantial share of this market due to high prevalence rates of rheumatoid arthritis and cancer. The broader generic oncology drugs market is projected to reach approximately USD 44.83 billion by 2032 with a CAGR of around 6.2%, while the autoimmune disease therapeutics market is expected to grow from an estimated $168.6 billion in 2025 to $226.2 billion by 2035, at a CAGR of 3.0%. Alembic's consistent track record with USFDA approvals, including for drugs like Dapagliflozin and Doxorubicin Hydrochloride Liposome Injection, highlights its capability in navigating regulatory pathways. However, the methotrexate market is highly competitive, with major players like Pfizer (Hospira) and Teva Pharmaceuticals holding significant shares.

Challenges, Analyst Views, and Future Projections

The generic methotrexate market faces significant price erosion due to extensive competition from numerous manufacturers. Alembic enters this market, which saw Hospira's original product as a benchmark, facing established players and aggressive pricing. The company's stock has experienced market pressures, including a decline of approximately 28% over the nine months preceding April 2025. While the consensus analyst rating for Alembic Pharmaceuticals is typically a 'Buy' with an average 12-month price target around ₹1000-₹1020 INR, some observers have expressed caution, reflected in recent price target reductions. The broader oncology and autoimmune drug markets are also subject to intense competition from newer, more effective biologics and targeted therapies. Analysts project Alembic's revenue to grow by 10.1% per annum over the next three years. Earnings are expected to increase at a faster rate of 20.8% annually, outpacing the Indian market's overall earnings growth forecast.